Article Figures & Data
Tables
- Table 1:
Baseline demographic and clinical characteristics according to no or poor (Tan 0–1) and moderate or good collaterals (Tan 2–3)
Tan 0–1 (n = 48) Tan 2–3 (n = 56) P Value Demographic characteristics Age (mean) (SD) (yr) 72.0 (11.7) 73.7 (4.3) .52a Female sex (No.) (%) 17 (35.4) 23 (41.1) .56b Premedication (No.) (%) Antiplatelets .5b No 33 (71.7) 38 (69.1) Aspirin 12 (26.1) 13 (23.6) Dual 1 (2.2) 4 (7.3) Missing 2 1 Oral anticoagulants No 42 (89.4) 36 (65.5) .01b Missing 1 1 Statins No 37 (80.4) 30 (56.6) .01b Missing 2 3 Vascular risk factors (No.) (%) Hypertension 37 (77.1) 37 (66.1) .22b Diabetes mellitus 13 (27.1) 10 (17.9) .26b Hyperlipidemia 12 (25.0) 17 (30.4) .54b Smokingc 11 (23.4) 4 (7.1) .02b Heart failure 10 (20.8) 19 (27.9) .14b Atrial fibrillation 24 (50) 30 (53.6) .72b Peripheral artery occlusive diseased 1 (2.1) 4 (7.4) .22b Pretreatment imaging (No.) (%) ASPECTS <.001b 10–8 24 (50) 47 (83.9) 7–6 22 (45.8) 7 (12.5) <6 2 (4.2) 2 (3.6) Median (IQR) 7 (6–9) 9 (8–10) Infarct volume (mean) (SD) (cm3) 107.4 (99.1) 35.0 (55.1) <.001a Scores on admission (No.) (%) Premorbid mRS .02e 0 30 (62.5) 24 (42.9) 1 11 (22.9) 10 (17.9) 2 4 (8.3) 14 (25) >2 3 (6.3) 8 (14.3) NIHSS on admission 17.9 (3.6) 16.9 (3.7) .14a GCS on admission .8e 12 6 (12.5) 2 (3.6) 13 21 (43.8) 31 (55.4) 15–14 21 (43.8) 23 (41.2) Occlusion (No.) (%) MCA 26 (54.2) 39 (69.6) .08b ICA 3 (6.3) 0 (0) ICA + MCA 19 (39.6) 17 (30.4) Occlusion side right 22 (45.8) 23 (44.1) .63b Treatment of stroke .24b IV tPA + EST 32 (66.7) 31 (55.4) EST 16 (33.3) 25 (44.6) - Table 2:
SIESTA primary and secondary outcome results according to no or poor (Tan 0–1) and moderate or good collaterals (Tan 2–3)
Tan 0–1 (n = 48) Tan 2–3 (n = 56) P Value Primary outcome Improvement in NIHSS (mean) (SD) −1.1 (10.7) −5.8 (7.6) .01a Secondary outcomes Clinical (No.) (%) mRS 0–2 after 3 mo 10 (20.8) 14 (25.0) .82b In-house mortality 7 (14.6) 1 (1.8) .02b Mortality after 3 mo 12 (25.0) 15 (26.8) .84b Logistics (mean) (SD) Length of stay in hospital (days) 6.0 (3.7) 4.6 (2.6) .06c Length of stay in ICU (half-days)e 8.2 (9.2) 2.7 (2.2) <.001c Length of ventilation (hr) 30.1 (5.9) 3.8 (5.4) .11c Length of stay on stroke unit (half-days)f 7.6 (4.3) 7.0 (4.3) .5c Onset-to-treatment (IV or IA) (min)g 122.8 (64.8) 129.6 (60.9) .61b Door-to-groin (min) 71.5 (32.1) 66.1 (21.4) .52c Door-to-reperfusion (min)h 174.8 (57.1) 165.6 (60.5) .32c Feasibility of EST (No.) (%) Degree of reperfusion (TICI) .97d 0–1 3 (6.3) 5 (9) 2a 4 (8.3) 3 (5.4) 2b 24 (50.0) 25 (44.6) 3 17 (35.4) 23 (41.1) Substantial patient movement 1 (2.1) 2 (3.6) .65b Difficult vascular approach 3 (6.3) 7 (12.5) .28b Other 3 (6.3) 8 (14.3) .18b Safety (No.) (%) Complications before EST Impaired monitor installation 0 (0.0) 1 (1.8) .35b Other 1 (2.1) 0 (0.0) .27b Complications during EST Critical ventilation or oxygenation disturbance 2 (4.2) 1 (1.8) .47b Intervention-associated complications 0 (0.0) 2 (3.6) .19b Vessel perforation with ICH and/or SAH complications after EST 0 (0.0) 2 (3.6) .19b Hyper- or hypothermia 12 (25.0) 12 (21.4) .67b Delayed extubation 17 (35.4) 12 (21.4) .11b Ventilation-associated complications 6 (12.5) 3 (5.4) .2b Ventilation-associated pneumonia 6 (12.5) 3 (5.4) .2b Note:—IA indicates intra-arterial; min, minimum; max, maximum; ICH, intracerebral hemorrhage; ICU, intensive care unit.
↵a ANCOVA, NIHSS as baseline covariate.
↵b χ2 test, 2-sided.
↵c t test, 2-sided.
↵d Mann-Whitney U test, 2-sided.
↵e Lower sample size (41 and 46).
↵f Lower sample size (31 and 51).
↵g Lower sample size (41 and 47).
↵h Lower sample size (45 and 49).
